3.7M
XNAS Volume
High volume today
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 54.25 per share. | 17 Mar 2025 | 4,000 | 13,130 (0%) | 0% | 54.3 | 217,000 | Common Stock |
| Asif Ali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 58.73 per share. | 12 Mar 2025 | 24,903 | 62,821 (0%) | 0% | 58.7 | 1,462,553 | Common Stock |
| Asif Ali | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 9,700 | 66,800 | - | - | Stock Option (right to buy) | |
| Asif Ali | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.17 per share. | 12 Mar 2025 | 15,203 | 78,024 (0%) | 0% | 12.2 | 185,021 | Common Stock |
| Asif Ali | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.19 per share. | 12 Mar 2025 | 9,700 | 87,724 (0%) | 0% | 19.2 | 186,143 | Common Stock |
| Asif Ali | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 15,203 | 30,547 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 24,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 05 Mar 2025 | 24,000 | 564,260 (2%) | 0% | 4.2 | 101,040 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 38.18 per share. | 19 Feb 2025 | 5,359 | 540,260 (1%) | 0% | 38.2 | 204,607 | Common Stock |
| Asif Ali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Jan 2025 | 2,601 | 62,821 (0%) | 0% | 0 | Common Stock | |
| Asif Ali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Jan 2025 | 1,317 | 65,422 (0%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 15 Jan 2025 | 12,636 | 545,619 (2%) | 0% | 0 | Common Stock | |
| Harold E. Selick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 6,584 | 6,584 | - | - | Stock Option (right to buy) | |
| Harold E. Selick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 5,130 | 33,126 (0%) | 0% | 0 | Common Stock | |
| Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 6,584 | 6,584 | - | - | Stock Option (right to buy) | |
| Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 5,130 | 5,130 (0%) | 0% | 0 | Common Stock | |
| William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 6,584 | 6,584 | - | - | Stock Option (right to buy) | |
| William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 5,130 | 17,130 (0%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 181,472 | 181,472 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 149,800 | 558,255 (2%) | 0% | 0 | Common Stock | |
| Bryan Giraudo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 5,130 | 15,130 (0%) | 0% | 0 | Common Stock | |
| Bryan Giraudo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 6,584 | 6,584 | - | - | Stock Option (right to buy) | |
| Asif Ali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 31,779 | 66,739 (0%) | 0% | 0 | Common Stock | |
| Asif Ali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 38,520 | 38,520 | - | - | Stock Option (right to buy) | |
| Patel V. Dinesh | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Nov 2024 | 7,000 | 428,208 (1%) | 0% | 0 | Common Stock | |
| Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.02 per share. | 25 Nov 2024 | 45,000 | 274,611 (1%) | 0% | 8.0 | 360,900 | Common Stock |
| Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 85,000 | 0 | - | - | Stock Option (right to buy) | |
| Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 450 | 93,300 | - | - | Stock Option (right to buy) | |
| Dinesh Patel V. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 46.25 per share. | 25 Nov 2024 | 21,480 | 408,455 (1%) | 0% | 46.3 | 993,450 | Common Stock |
| V. Patel Dinesh | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.58 per share. | 25 Nov 2024 | 1,727 | 429,935 (1%) | 0% | 21.6 | 37,269 | Common Stock |
| V. Patel Dinesh | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 1,727 | 318,273 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 46.96 per share. | 25 Nov 2024 | 78,520 | 435,208 (1%) | 0% | 47.0 | 3,687,299 | Common Stock |
| Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 25 Nov 2024 | 85,000 | 359,611 (1%) | 0% | 7.8 | 663,000 | Common Stock |
| Gupta Suneel | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 45.50 per share. | 25 Nov 2024 | 19,191 | 266,983 (0%) | 0% | 45.5 | 873,191 | Common Stock |
| Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.17 per share. | 25 Nov 2024 | 30,000 | 286,174 (1%) | 0% | 12.2 | 365,100 | Common Stock |
| Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 45,000 | 0 | - | - | Stock Option (right to buy) | |
| Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 30,000 | 93,750 | - | - | Stock Option (right to buy) | |
| Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.17 per share. | 25 Nov 2024 | 450 | 267,433 (0%) | 0% | 12.2 | 5,477 | Common Stock |
| Suneel Gupta | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 46.04 per share. | 25 Nov 2024 | 103,437 | 256,174 (0%) | 0% | 46.0 | 4,762,239 | Common Stock |
| Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.38 per share. | 25 Nov 2024 | 45,000 | 229,611 (0%) | 0% | 7.4 | 332,100 | Common Stock |
| Gupta Suneel | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 45,000 | 0 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Nov 2024 | 1,000 | 513,415 (1%) | 0% | 0 | Common Stock | |
| Asif Ali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 44.59 per share. | 11 Sep 2024 | 2,203 | 34,960 (0%) | 0% | 44.6 | 98,232 | Common Stock |
| Asif Ali | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 6,000 | 76,500 | - | - | Stock Option (right to buy) | |
| Asif Ali | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 6,000 | 45,750 | - | - | Stock Option (right to buy) | |
| Asif Ali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 44.47 per share. | 11 Sep 2024 | 12,000 | 34,960 (0%) | 0% | 44.5 | 533,640 | Common Stock |
| Asif Ali | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.17 per share. | 11 Sep 2024 | 6,000 | 46,960 (0%) | 0% | 12.2 | 73,020 | Common Stock |
| Asif Ali | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.19 per share. | 11 Sep 2024 | 6,000 | 40,960 (0%) | 0% | 19.2 | 115,140 | Common Stock |
| William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.88 per share. | 10 Sep 2024 | 8,000 | 20,000 (0%) | 0% | 12.9 | 103,040 | Common Stock |
| William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 8,000 | 0 | - | - | Stock Option (right to buy) | |
| William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 10 Sep 2024 | 8,000 | 12,000 (0%) | 0% | 45 | 360,000 | Common Stock |
| William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2024 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 24 Jul 2024 | 8,000 | 12,000 (0%) | 0% | 40 | 320,000 | Common Stock |
| William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.88 per share. | 24 Jul 2024 | 8,000 | 20,000 (0%) | 0% | 12.9 | 103,040 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jun 2024 | 1,000 | 514,415 (1%) | 0% | 0 | Common Stock | |
| William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 8,000 | 16,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 07 Jun 2024 | 8,000 | 12,000 (0%) | 0% | 35 | 280,000 | Common Stock |
| William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.88 per share. | 07 Jun 2024 | 8,000 | 20,000 (0%) | 0% | 12.9 | 103,040 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.19 per share. | 07 Jun 2024 | 35,000 | 515,415 (1%) | 0% | 35.2 | 1,231,650 | Common Stock |
| Asif Ali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.11 per share. | 18 Apr 2024 | 1,234 | 37,163 (0%) | 0% | 25.1 | 30,986 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 28.31 per share. | 01 Apr 2024 | 25,000 | 549,590 (2%) | 0% | 28.3 | 707,750 | Common Stock |
| Harold E. Selick | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 6,490 | 0 | - | - | Stock Option (right to buy) | |
| Harold E. Selick | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 07 Mar 2024 | 6,490 | 27,996 (0%) | 0% | 1.9 | 12,266 | Common Stock |
| William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 12,975 | 0 | - | - | Stock Option (right to buy) | |
| William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 31.34 per share. | 01 Mar 2024 | 12,975 | 12,000 (0%) | 0% | 31.3 | 406,637 | Common Stock |
| William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.09 per share. | 01 Mar 2024 | 12,975 | 24,975 (0%) | 0% | 6.1 | 79,018 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 31.62 per share. | 01 Mar 2024 | 30,000 | 574,590 (2%) | 0% | 31.6 | 948,600 | Common Stock |
| Asif Ali | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.17 per share. | 29 Feb 2024 | 12,000 | 52,645 (0%) | 0% | 12.2 | 146,040 | Common Stock |
| Asif Ali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.61 per share. | 29 Feb 2024 | 7,850 | 42,734 (0%) | 0% | 30.6 | 240,289 | Common Stock |
| Asif Ali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.00 per share. | 29 Feb 2024 | 2,089 | 40,645 (0%) | 0% | 31 | 64,759 | Common Stock |
| Asif Ali | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 12,000 | 51,750 | - | - | Stock Option (right to buy) | |
| Asif Ali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.33 per share. | 29 Feb 2024 | 2,248 | 38,397 (0%) | 0% | 32.3 | 72,678 | Common Stock |
| Asif Ali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.22 per share. | 29 Feb 2024 | 12,000 | 40,645 (0%) | 0% | 32.2 | 386,640 | Common Stock |
| Patel V. Dinesh | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.53 per share. | 26 Feb 2024 | 10,915 | 604,590 (2%) | 0% | 29.5 | 322,320 | Common Stock |
| Gupta Suneel | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.53 per share. | 26 Feb 2024 | 4,282 | 183,285 (0%) | 0% | 29.5 | 126,447 | Common Stock |
| Patel Dinesh V. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.23 per share. | 15 Feb 2024 | 3,717 | 615,505 (2%) | 0% | 28.2 | 104,931 | Common Stock |
| Asif Ali | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.63 per share. | 16 Jan 2024 | 1,452 | 50,584 (0%) | 0% | 24.6 | 35,763 | Common Stock |
| Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.38 per share. | 09 Jan 2024 | 5,000 | 192,567 (0%) | 0% | 7.4 | 36,900 | Common Stock |
| Gupta Suneel | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 09 Jan 2024 | 5,000 | 187,567 (0%) | 0% | 25 | 125,000 | Common Stock |
| Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2024 | 5,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 19,250 | 187,567 (0%) | 0% | 0 | Common Stock | |
| V. Dinesh Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 315,250 | 315,250 | - | - | Stock Option (right to buy) | |
| Williams Lewis T. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 25,700 | 25,700 | - | - | Stock Option (right to buy) | |
| Ali Asif | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 21,000 | 52,036 (0%) | 0% | 0 | Common Stock | |
| William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 25,700 | 25,700 | - | - | Stock Option (right to buy) | |
| Patel Dinesh V. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 84,875 | 619,222 (2%) | 0% | 0 | Common Stock | |
| Gupta Suneel | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 71,500 | 71,500 | - | - | Stock Option (right to buy) | |
| Asif Ali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 78,000 | 78,000 | - | - | Stock Option (right to buy) | |
| Giraudo Bryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 25,700 | 25,700 | - | - | Stock Option (right to buy) | |
| Selick E. Harold | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 25,700 | 25,700 | - | - | Stock Option (right to buy) | |
| Dinesh Patel V. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.08 per share. | 13 Dec 2023 | 75,000 | 534,347 (1%) | 0% | 20.1 | 1,506,000 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 May 2023 | 10,000 | 583,448 (2%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.07 per share. | 31 May 2023 | 12,165 | 602,946 (2%) | 0% | 26.1 | 317,142 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 30,000 | 615,111 (2%) | 0% | 0 | Common Stock | |
| Suneel Gupta | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.07 per share. | 31 May 2023 | 4,150 | 148,037 (0%) | 0% | 26.1 | 108,191 | Common Stock |
| Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 12,000 | 152,187 (0%) | 0% | 0 | Common Stock | |
| Asif Ali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 12,000 | 35,186 (0%) | 0% | 0 | Common Stock | |
| Asif Ali | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.07 per share. | 31 May 2023 | 4,150 | 31,036 (0%) | 0% | 26.1 | 108,191 | Common Stock |
| Asif Ali | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.21 per share. | 18 Apr 2023 | 1,189 | 23,186 (0%) | 0% | 23.2 | 27,597 | Common Stock |
| Harold E. Selick | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 6,196 | 0 | - | - | Stock Option (right to buy) | |
| Harold E. Selick | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.87 per share. | 10 Apr 2023 | 6,196 | 21,506 (0%) | 0% | 0.9 | 5,391 | Common Stock |
| Harold E. Selick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jan 2023 | 3,000 | 581,048 (2%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 600,000 | 600,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jan 2023 | 3,116 | 598,096 (2%) | 0% | 0 | Common Stock | |
| Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Bryan Giraudo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 123,750 | 123,750 | - | - | Stock Option (right to buy) | |
| Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 20,625 | 138,187 (0%) | 0% | 0 | Common Stock | |
| Asif Ali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 63,750 | 63,750 | - | - | Stock Option (right to buy) | |
| Asif Ali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 10,625 | 24,375 (0%) | 0% | 0 | Common Stock | |
| David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.87 per share. | 16 Nov 2022 | 13,767 | 80,878 (0%) | 0% | 0.9 | 11,977 | Common Stock |
| David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 35,331 | 0 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 35,656 | 0 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 5,999 | 0 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 9,726 | 0 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 13,767 | 0 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 16 Nov 2022 | 35,331 | 167,590 (0%) | 0% | 4.2 | 148,744 | Common Stock |
| David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 16 Nov 2022 | 35,656 | 132,259 (0%) | 0% | 1.2 | 41,361 | Common Stock |
| David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 16 Nov 2022 | 5,999 | 96,603 (0%) | 0% | 1.9 | 11,338 | Common Stock |
| David Y. Liu | Chief R&D Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 16 Nov 2022 | 9,726 | 90,604 (0%) | 0% | 1.9 | 18,382 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2022 | 20,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 23 Aug 2022 | 20,000 | 604,048 (2%) | 0% | 4.2 | 84,200 | Common Stock |
| Harold E. Selick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Bryan Giraudo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 04 May 2022 | 15,742 | 584,048 (2%) | 0% | 4.2 | 66,274 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 15,742 | 80,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.59 per share. | 03 May 2022 | 12,000 | 12,000 (0%) | 0% | 8.6 | 103,080 | Common Stock |
| William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 12,000 | 0 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2022 | 30,000 | 95,742 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 26 Apr 2022 | 30,000 | 568,306 (2%) | 0% | 4.2 | 126,300 | Common Stock |
| Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2022 | 40,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Suneel Gupta | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.38 per share. | 26 Apr 2022 | 40,000 | 117,561 (0%) | 0% | 7.4 | 295,200 | Common Stock |
| Asif Ali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2022 | 13,750 | 13,750 (0%) | 0% | 0 | Common Stock | |
| Asif Ali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2022 | 82,500 | 82,500 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 14 Apr 2022 | 34,087 | 537,847 (1%) | 0% | 1.9 | 64,424 | Common Stock |
| Dinesh V. Patel | Director, President and CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2022 | 34,087 | 0 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.28 per share. | 28 Feb 2022 | 4,648 | 503,760 (1%) | 0% | 24.3 | 112,853 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.28 per share. | 28 Feb 2022 | 2,119 | 66,538 (0%) | 0% | 24.3 | 51,449 | Common Stock |
| Suneel Gupta | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.28 per share. | 28 Feb 2022 | 649 | 77,007 (0%) | 0% | 24.3 | 15,758 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 31,250 | 508,408 (1%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 187,500 | 187,500 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 10,000 | 68,657 (0%) | 0% | 0 | Common Stock | |
| Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 12,500 | 77,656 (0%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.14 per share. | 21 Dec 2021 | 15,000 | 477,158 (1%) | 0% | 32.1 | 482,171 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 40,000 | 125,742 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 21 Sep 2021 | 40,000 | 492,158 (1%) | 0% | 4.2 | 168,400 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 10,000 | 13,767 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 47.56 per share. | 17 Aug 2021 | 14,779 | 58,254 (0%) | 0% | 47.6 | 702,889 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.87 per share. | 17 Aug 2021 | 10,000 | 73,033 (0%) | 0% | 0.9 | 8,700 | Common Stock |
| Harold E. Selick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Bryan Giraudo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Samuel R. Saks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 12,000 | 14,000 (0%) | 0% | 0 | Common Stock | |
| Samuel R. Saks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 25,000 | 451,144 (1%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 10,000 | 62,427 (0%) | 0% | 0 | Common Stock | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 12,000 | 63,987 (0%) | 0% | 0 | Common Stock | |
| Sarah B. Noonberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 4,700 | 7,300 | - | - | Stock Option (right to buy) | |
| Sarah B. Noonberg | Director | Sale of securities on an exchange or to another person at price $ 25.09 per share. | 10 Feb 2021 | 3,700 | 0 (0%) | 0% | 25.1 | 92,833 | Common Stock |
| Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 6.98 per share. | 10 Feb 2021 | 3,700 | 3,700 (0%) | 0% | 7.0 | 25,826 | Common Stock |
| Sarah B. Noonberg | Director | Sale of securities on an exchange or to another person at price $ 26.04 per share. | 10 Feb 2021 | 400 | 0 (0%) | 0% | 26.0 | 10,416 | Common Stock |
| Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 6.98 per share. | 10 Feb 2021 | 4,700 | 4,700 (0%) | 0% | 7.0 | 32,806 | Common Stock |
| Sarah B. Noonberg | Director | Sale of securities on an exchange or to another person at price $ 25.42 per share. | 10 Feb 2021 | 4,300 | 400 (0%) | 0% | 25.4 | 109,306 | Common Stock |
| Sarah B. Noonberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 3,700 | 3,600 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 24.60 per share. | 19 Jan 2021 | 24,846 | 426,144 (1%) | 0% | 24.6 | 611,105 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 13,000 | 165,742 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 19 Jan 2021 | 13,000 | 450,990 (1%) | 0% | 4.2 | 54,730 | Common Stock |
| Chaitan S. Khosla | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2020 | 2,499 | 7,499 | - | - | Stock Option (right to buy) | |
| Chaitan S. Khosla | None | Sale of securities on an exchange or to another person at price $ 17.19 per share. | 11 Aug 2020 | 2,499 | 0 (0%) | 0% | 17.2 | 42,952 | Common Stock |
| Chaitan S. Khosla | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 11 Aug 2020 | 2,499 | 2,499 (0%) | 0% | 1.9 | 4,723 | Common Stock |
| Chaitan S. Khosla | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Harold E. Selick | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Lewis T. Williams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Sarah B. Noonberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Bryan Giraudo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Apr 2020 | 2,000 | 437,990 (1%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2020 | 10,000 | 34,087 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 20 Mar 2020 | 10,000 | 439,990 (1%) | 0% | 1.9 | 18,900 | Common Stock |
| Harold E. Selick | None | Purchase of securities on an exchange or from another person at price $ 6.70 per share. | 12 Mar 2020 | 12,000 | 15,310 (0%) | 0% | 6.7 | 80,400 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2020 | 18,344 | 0 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 12 Mar 2020 | 18,344 | 429,990 (1%) | 0% | 1.2 | 21,279 | Common Stock |
| Samuel R. Saks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 85,000 | 85,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 235,000 | 235,000 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Suneel Gupta | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 85,000 | 85,000 | - | - | Stock Option (right to buy) | |
| Donald Kalkofen | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.10 per share. | 03 Dec 2019 | 613 | 613 (0%) | 0% | 5.1 | 3,126 | Common Stock |
| Donald Kalkofen | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.09 per share. | 03 Dec 2019 | 562 | 1,175 (0%) | 0% | 5.1 | 2,861 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 5.55 per share. | 03 Dec 2019 | 10,000 | 389,824 (1%) | 0% | 5.6 | 55,500 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 5.65 per share. | 03 Dec 2019 | 20,000 | 409,824 (1%) | 0% | 5.7 | 113,000 | Common Stock |
| Bryan Giraudo | Director | Purchase of securities on an exchange or from another person at price $ 5.70 per share. | 03 Dec 2019 | 8,000 | 8,000 (0%) | 0% | 5.7 | 45,620 | Common Stock |
| Suneel Gupta | EVP Clinical Operations | Purchase of securities on an exchange or from another person at price $ 5.13 per share. | 03 Dec 2019 | 30,000 | 49,500 (0%) | 0% | 5.1 | 153,900 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 26 Nov 2019 | 4,000 | 379,824 (1%) | 0% | 1.2 | 4,640 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2019 | 4,000 | 18,343 | - | - | Stock Option (right to buy) | |
| Chaitan S. Khosla | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.85 per share. | 06 Aug 2019 | 10,792 | 374,792 (1%) | 0% | 8.9 | 95,535 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.85 per share. | 06 Aug 2019 | 3,395 | 49,802 (0%) | 0% | 8.8 | 30,044 | Common Stock |
| Chaitan S. Khosla | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2019 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Harold E. Selick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2019 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2019 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2019 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2019 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Bryan Giraudo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2019 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Donald Kalkofen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2019 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Samuel R. Saks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2019 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Harold E. Selick | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.31 per share. | 01 Apr 2019 | 3,310 | 3,310 (0%) | 0% | 1.3 | 4,336 | Common Stock |
| Harold E. Selick | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2019 | 3,310 | 0 | - | - | Stock Option (right to buy) | |
| Samuel R. Saks | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Samuel R. Saks | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 2,500 | 2,500 (0%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 172,500 | 172,500 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.03 per share. | 28 Feb 2019 | 2,183 | 383,831 (1%) | 0% | 8.0 | 17,529 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 28,750 | 386,014 (1%) | 0% | 0 | Common Stock | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 15,000 | 52,007 (0%) | 0% | 0 | Common Stock | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.03 per share. | 28 Feb 2019 | 810 | 51,197 (0%) | 0% | 8.0 | 6,504 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.03 per share. | 28 Feb 2019 | 657 | 32,021 (0%) | 0% | 8.0 | 5,276 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 51,000 | 51,000 | - | - | Stock Option (right to buy) | |
| Richard S. Shames | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 8,500 | 32,678 (0%) | 0% | 0 | Common Stock | |
| Suneel Gupta | EVP Clinical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Suneel Gupta | EVP Clinical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2019 | 7,500 | 17,500 (0%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.10 per share. | 06 Feb 2019 | 777 | 367,396 (1%) | 0% | 8.1 | 6,292 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.71 per share. | 06 Feb 2019 | 10,132 | 357,264 (1%) | 0% | 7.7 | 78,118 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.74 per share. | 06 Feb 2019 | 3,821 | 37,007 (0%) | 0% | 7.7 | 29,562 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.15 per share. | 06 Feb 2019 | 198 | 26,758 (0%) | 0% | 8.2 | 1,614 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.71 per share. | 06 Feb 2019 | 2,580 | 24,178 (0%) | 0% | 7.7 | 19,892 | Common Stock |
| Suneel Gupta | EVP Clinical Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2019 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 11 Jan 2019 | 22,344 | 368,173 (1%) | 0% | 1.2 | 25,919 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2019 | 22,344 | 22,343 | - | - | Stock Option (right to buy) | |
| Thomas P. O'Neil | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 21,100 | 30,560 (0%) | 0% | 0 | Common Stock | |
| Thomas P. O'Neil | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 14,050 | 14,050 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 82,050 | 345,829 (1%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 54,700 | 54,700 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 25,800 | 40,828 (0%) | 0% | 0 | Common Stock | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 17,200 | 17,200 | - | - | Stock Option (right to buy) | |
| Richard S. Shames | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 18,750 | 26,956 (0%) | 0% | 0 | Common Stock | |
| Richard S. Shames | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2018 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Jul 2018 | 2,000 | 263,779 (1%) | 0% | 0 | Common Stock | |
| Samuel R. Saks | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2018 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Chaitan S. Khosla | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Harold E. Selick | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Lewis T. Williams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Armen Shanafelt | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Sarah B. Noonberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Bryan Giraudo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2018 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Chaitan S. Khosla | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2018 | 3,000 | 3,000 | - | - | Stock Option (right to buy) | |
| Bryan Giraudo | None | Purchase of securities on an exchange or from another person at price $ 6.46 per share. | 15 May 2018 | 10,000 | 10,000 (0%) | 0% | 6.5 | 64,566 | Common Stock |
| Bryan Giraudo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2018 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 10 May 2018 | 13,516 | 265,779 (1%) | 0% | 1.2 | 15,679 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2018 | 13,516 | 44,687 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2018 | 20,000 | 58,203 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 02 Apr 2018 | 20,000 | 252,263 (1%) | 0% | 1.2 | 23,200 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.87 per share. | 26 Mar 2018 | 11,298 | 232,263 (1%) | 0% | 0.9 | 9,829 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2018 | 11,298 | 0 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 12 Mar 2018 | 3,500 | 18,528 (0%) | 0% | 4.2 | 14,735 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2018 | 3,500 | 35,331 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.29 per share. | 12 Mar 2018 | 3,500 | 15,028 (0%) | 0% | 21.3 | 74,500 | Common Stock |
| Thomas P. O'Neil | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 34,000 | 34,000 | - | - | Stock Option (right to buy) | |
| Thomas P. O'Neil | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 6,000 | 8,858 (0%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 25,000 | 219,259 (1%) | 0% | 0 | Common Stock | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 28 Feb 2018 | 875 | 13,322 (0%) | 0% | 20 | 17,500 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 9,500 | 13,322 (0%) | 0% | 0 | Common Stock | |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 28 Feb 2018 | 875 | 14,197 (0%) | 0% | 1.9 | 1,654 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2018 | 875 | 9,725 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 56,500 | 56,500 | - | - | Employee Stock Option (right to buy) | |
| Richard S. Shames | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 6,500 | 6,500 (0%) | 0% | 0 | Common Stock | |
| Richard S. Shames | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 37,500 | 37,500 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2018 | 875 | 10,600 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 16 Jan 2018 | 875 | 3,822 (0%) | 0% | 20 | 17,500 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 16 Jan 2018 | 875 | 4,697 (0%) | 0% | 1.9 | 1,654 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.50 per share. | 22 Dec 2017 | 3,529 | 0 (0%) | 0% | 20.5 | 72,345 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2017 | 3,529 | 33,273 | - | - | Stock Option (right to buy) | |
| Richard S. Shames | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 22 Dec 2017 | 3,529 | 3,529 (0%) | 0% | 4.2 | 14,857 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2017 | 8,210 | 44,087 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 21 Dec 2017 | 8,210 | 198,647 (0%) | 0% | 1.9 | 15,517 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.56 per share. | 21 Dec 2017 | 8,210 | 190,437 (0%) | 0% | 19.6 | 160,570 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 20 Dec 2017 | 1,790 | 192,227 (0%) | 0% | 1.9 | 3,383 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2017 | 1,790 | 52,297 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.55 per share. | 20 Dec 2017 | 1,790 | 190,437 (0%) | 0% | 19.5 | 34,987 | Common Stock |
| Thomas P. O'Neil | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2017 | 4,000 | 57,666 | - | - | Employee Stock Option (right to buy) | |
| Thomas P. O'Neil | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 18 Dec 2017 | 4,000 | 8,000 (0%) | 0% | 4.2 | 16,840 | Common Stock |
| Thomas P. O'Neil | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 18 Dec 2017 | 4,000 | 4,000 (0%) | 0% | 1.2 | 4,640 | Common Stock |
| Thomas P. O'Neil | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 18 Dec 2017 | 8,000 | 0 (0%) | 0% | 20 | 160,000 | 12/18/2017 |
| Thomas P. O'Neil | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2017 | 4,000 | 28,998 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 18 Dec 2017 | 875 | 4,697 (0%) | 0% | 1.9 | 1,654 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2017 | 875 | 11,475 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 18 Dec 2017 | 875 | 3,822 (0%) | 0% | 20 | 17,500 | Common Stock |
| Sarah B. Noonberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2017 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 30 Nov 2017 | 875 | 3,822 (0%) | 0% | 20 | 17,500 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.89 per share. | 30 Nov 2017 | 875 | 4,697 (0%) | 0% | 1.9 | 1,654 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2017 | 875 | 12,350 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 13 Nov 2017 | 3,500 | 7,322 (0%) | 0% | 1.9 | 6,615 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 13 Nov 2017 | 3,500 | 7,322 (0%) | 0% | 4.2 | 14,735 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2017 | 3,500 | 38,831 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2017 | 3,500 | 13,225 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.97 per share. | 13 Nov 2017 | 3,500 | 3,822 (0%) | 0% | 17.0 | 59,381 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.97 per share. | 13 Nov 2017 | 3,500 | 3,822 (0%) | 0% | 17.0 | 59,381 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 05 Oct 2017 | 2,017 | 0 (0%) | 0% | 19 | 38,323 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2017 | 2,017 | 36,802 | - | - | Stock Option (right to buy) | |
| Richard S. Shames | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 05 Oct 2017 | 2,017 | 2,017 (0%) | 0% | 4.2 | 8,492 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.31 per share. | 12 Sep 2017 | 3,687 | 0 (0%) | 0% | 14.3 | 52,753 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 29 Aug 2017 | 1,512 | 1,865 (0%) | 0% | 17 | 25,704 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 29 Aug 2017 | 1,512 | 3,377 (0%) | 0% | 4.2 | 6,366 | Common Stock |
| Richard S. Shames | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2017 | 1,512 | 38,819 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 28 Aug 2017 | 3,500 | 5,500 (0%) | 0% | 4.2 | 14,735 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 28 Aug 2017 | 3,500 | 2,000 (0%) | 0% | 15 | 52,500 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2017 | 3,500 | 42,331 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2017 | 3,500 | 16,725 | - | - | Employee Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.68 per share. | 10 Jul 2017 | 3,500 | 2,000 (0%) | 0% | 12.7 | 44,380 | Common Stock |
| David Y. Liu | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 10 Jul 2017 | 3,500 | 5,500 (0%) | 0% | 1.9 | 6,615 | Common Stock |
| Lewis T. Williams | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2017 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Chaitan S. Khosla | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2017 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Harold E. Selick | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2017 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2017 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Armen Shanafelt | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2017 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Julie Papanek | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2017 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2017 | 19,099 | 78,203 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 09 May 2017 | 19,099 | 190,437 (1%) | 0% | 1.2 | 22,155 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 06 Apr 2017 | 20,000 | 171,338 (1%) | 0% | 1.2 | 23,200 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2017 | 20,000 | 97,302 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2017 | 16,362 | 11,297 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.87 per share. | 10 Mar 2017 | 16,362 | 151,338 (0%) | 0% | 0.9 | 14,235 | Common Stock |
| Dinesh V. Patel | Director, President and CEO | 31 Dec 2016 | 3,000 | 27,659 | - | - | Stock Option (right to buy) | ||
| Dinesh V. Patel | Director, President and CEO | 31 Dec 2016 | 3,000 | 134,976 | - | - | Common Stock | ||
| Thomas P. O'Neil | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2016 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2016 | 320,000 | 320,000 | - | - | Stock Option (right to buy) | |
| David Y. Liu | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2016 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Richard S. Shames | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2016 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| William Hodder | Sr. VP - Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2016 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Harold E. Selick | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2016 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Chaitan S. Khosla | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2016 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| William D. Waddill | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2016 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Armen Shanafelt | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2016 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Julie Papanek | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2016 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| S. Edward Torres | Ten Percent Owner | 16 Aug 2016 | 3,000,000 | 0 | - | - | Series A Preferred Stock | ||
| S. Edward Torres | Ten Percent Owner | 16 Aug 2016 | 9,142,857 | 0 | - | - | Series B Preferred Stock | ||
| S. Edward Torres | Ten Percent Owner | 16 Aug 2016 | 9,841,333 | 0 | - | - | Series C Preferred Stock | ||
| S. Edward Torres | Ten Percent Owner | 16 Aug 2016 | 206,896 | 206,896 | - | - | Common Stock | ||
| S. Edward Torres | Ten Percent Owner | 16 Aug 2016 | 630,541 | 837,437 | - | - | Common Stock | ||
| S. Edward Torres | Ten Percent Owner | 16 Aug 2016 | 678,712 | 1,516,149 | - | - | Common Stock | ||
| S. Edward Torres | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Aug 2016 | 583,333 | 2,099,482 | - | - | Common Stock | |
| Armen Shanafelt | Director, Ten Percent Owner | 16 Aug 2016 | 3,000,000 | 0 | - | - | Series A Preferred Stock | ||
| Armen Shanafelt | Director, Ten Percent Owner | 16 Aug 2016 | 9,142,857 | 0 | - | - | Series B Preferred Stock | ||
| Armen Shanafelt | Director, Ten Percent Owner | 16 Aug 2016 | 9,841,333 | 0 | - | - | Series C Preferred Stock | ||
| Armen Shanafelt | Director, Ten Percent Owner | 16 Aug 2016 | 206,896 | 206,896 | - | - | Common Stock | ||
| Armen Shanafelt | Director, Ten Percent Owner | 16 Aug 2016 | 630,541 | 837,437 | - | - | Common Stock | ||
| Armen Shanafelt | Director, Ten Percent Owner | 16 Aug 2016 | 678,712 | 1,516,149 | - | - | Common Stock | ||
| Armen Shanafelt | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Aug 2016 | 583,333 | 2,099,482 | - | - | Common Stock | |
| Julie Papanek | None | 16 Aug 2016 | 27,113,877 | 0 | - | - | Series C Preferred Stock | ||
| Julie Papanek | None | 16 Aug 2016 | 1,869,922 | 1,869,922 | - | - | Common Stock | ||
| Julie Papanek | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Aug 2016 | 583,333 | 2,453,255 | - | - | Common Stock |